Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNK-1411 in Duchenne Muscular Dystrophy
NCT03400852Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Feb 2020
- Modality
- Peptides
- Countries
- 8
01
Overview
A Phase 2 trial of MNK-1411 in Duchenne muscular dystrophy (DMD), sponsored by Mallinckrodt Pharmaceuticals. Started Jul 2018; status: terminated.
02
Drugs
MNK-1411
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03400852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400852.